Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week Open-Label Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

NCT04000009 is registered in ClinicalTrials.gov with ACADIA Pharmaceuticals Inc. as lead sponsor.

NCT NCT04000009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04000009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week Open-Label Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
Lead sponsor
ACADIA Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Terminated
Start date
June 6, 2019
Completion date
February 22, 2021
Enrollment
235 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

adjunctive treatment of major depressive disorder